We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
VKTX Advances Obesity Program With New Oral Maintenance Study
Read MoreHide Full Article
Key Takeaways
Viking launched a study testing oral and injectable VK2735 maintenance regimens for obesity.
Earlier results showed every-other-week and monthly dosing retained about 90% and 85% of prior weight loss.
VK2735 remains Viking's lead obesity candidate, with oral phase III development planned for late 2026.
Viking Therapeutics (VKTX - Free Report) announced the initiation of a clinical study evaluating oral maintenance dosing of its lead obesity candidate, VK2735.
The study, which is designed to enroll approximately 195 adults with obesity, will evaluate whether weight loss achieved with weekly subcutaneous (SC) VK2735 can be maintained using oral tablets or less frequent injections.
All participants will initially receive weekly SC VK2735 or placebo for 21 weeks. After the induction period, patients who received the drug will transition to different maintenance regimens, including daily or weekly oral doses of VK2735, monthly or every-other-week subcutaneous VK2735 or placebo. The study will evaluate safety, tolerability and pharmacokinetics, while exploratory measures will assess changes in body weight through week 33.
The oral formulation could provide an important convenience advantage if it successfully maintains weight loss. A data readout from this study is expected in 2027.
Year to date, the company’s shares have lost 19.4% against the industry’s 3.6% growth.
Image Source: Zacks Investment Research
Earlier Results Support Maintenance Potential for VKTX
Viking’s newly launched study is the second part of its two-part weight-maintenance program, expanding VK2735 beyond weekly injections. The initiation of part 2 follows encouraging results from part 1 of the maintenance study announced last month. During the 21-week induction phase, patients receiving weekly SC VK2735 achieved approximately 16% to 19% weight loss compared with a 0.1% decline for placebo.
Notably, much of the weight loss was maintained after a reduction in injection frequency. Patients switched to every-other-week dosing retained about 90% of their previous weight loss, while those receiving monthly dosing retained roughly 85%. By comparison, patients switched to placebo retained about 61% of their prior weight loss.
These findings suggest that VK2735 may have potential not only as a weight-loss treatment but also as a maintenance therapy that could reduce dosing frequency after initial weight loss is achieved.
VK2735 Remains the Key Pipeline Driver for VKTX
VK2735 is the company's lead obesity candidate and primary value driver. It is an investigational novel dual GLP-1 and GIP receptor agonist, being developed in both subcutaneous and oral formulations, positioning it as one of the more promising late-stage obesity therapies currently under development.
The company is conducting two late-stage studies — VANQUISH-1 and VANQUISH-2 — evaluating VK2735 SC for 78 weeks. VANQUISH-1 is evaluating the drug in adults without type II diabetes (T2D) who have obesity or are overweight with at least one weight-related co-morbid condition. VANQUISH-2 is assessing its efficacy in obese or overweight adults with T2D. Data from these studies are not expected before 2027.
Both studies are testing weekly doses of 7.5 mg, 12.5 mg and 17.5 mg against placebo. The phase III program is expected to provide important data on the long-term efficacy and safety of VK2735 in different patient populations.
Viking is on track to start late-stage studies of oral VK2735 by the end of this year, following encouraging phase II VENTURE-Oral results.
Competition in Targeted Markets Remains a Concern
Viking is developing the candidate as a potential alternative to established GLP-1 products marketed by pharma giants Eli Lilly (LLY - Free Report) and Novo Nordisk (NVO - Free Report) . Both companies are already marketing oral and injectable obesity treatments. Lilly markets injectable Zepbound and oral Foundayo, while Novo Nordisk markets injectable Wegovy and its oral Wegovy pill.
The competitive landscape is also evolving rapidly. Lilly recently reported results for EloraTZP, an investigational combination of eloralintide, a selective amylin receptor agonist and Zepbound. Data from a phase IIb study showed that all EloraTZP combinations met the primary and secondary endpoints, delivering substantial weight loss and A1C reductions at 48 weeks. LLY plans to advance the candidate into phase III development in the fourth quarter of 2026.
Meanwhile, Novo Nordisk has submitted CagriSema to the FDA for weight management. The once-weekly treatment combines semaglutide with cagrilintide, a long-acting amylin receptor agonist. A final decision is expected before this year’s end.
View the Zacks #1 Rank List
Image: Bigstock
VKTX Advances Obesity Program With New Oral Maintenance Study
Key Takeaways
Viking Therapeutics (VKTX - Free Report) announced the initiation of a clinical study evaluating oral maintenance dosing of its lead obesity candidate, VK2735.
The study, which is designed to enroll approximately 195 adults with obesity, will evaluate whether weight loss achieved with weekly subcutaneous (SC) VK2735 can be maintained using oral tablets or less frequent injections.
All participants will initially receive weekly SC VK2735 or placebo for 21 weeks. After the induction period, patients who received the drug will transition to different maintenance regimens, including daily or weekly oral doses of VK2735, monthly or every-other-week subcutaneous VK2735 or placebo. The study will evaluate safety, tolerability and pharmacokinetics, while exploratory measures will assess changes in body weight through week 33.
The oral formulation could provide an important convenience advantage if it successfully maintains weight loss. A data readout from this study is expected in 2027.
Year to date, the company’s shares have lost 19.4% against the industry’s 3.6% growth.
Image Source: Zacks Investment Research
Earlier Results Support Maintenance Potential for VKTX
Viking’s newly launched study is the second part of its two-part weight-maintenance program, expanding VK2735 beyond weekly injections. The initiation of part 2 follows encouraging results from part 1 of the maintenance study announced last month. During the 21-week induction phase, patients receiving weekly SC VK2735 achieved approximately 16% to 19% weight loss compared with a 0.1% decline for placebo.
Notably, much of the weight loss was maintained after a reduction in injection frequency. Patients switched to every-other-week dosing retained about 90% of their previous weight loss, while those receiving monthly dosing retained roughly 85%. By comparison, patients switched to placebo retained about 61% of their prior weight loss.
These findings suggest that VK2735 may have potential not only as a weight-loss treatment but also as a maintenance therapy that could reduce dosing frequency after initial weight loss is achieved.
VK2735 Remains the Key Pipeline Driver for VKTX
VK2735 is the company's lead obesity candidate and primary value driver. It is an investigational novel dual GLP-1 and GIP receptor agonist, being developed in both subcutaneous and oral formulations, positioning it as one of the more promising late-stage obesity therapies currently under development.
The company is conducting two late-stage studies — VANQUISH-1 and VANQUISH-2 — evaluating VK2735 SC for 78 weeks. VANQUISH-1 is evaluating the drug in adults without type II diabetes (T2D) who have obesity or are overweight with at least one weight-related co-morbid condition. VANQUISH-2 is assessing its efficacy in obese or overweight adults with T2D. Data from these studies are not expected before 2027.
Both studies are testing weekly doses of 7.5 mg, 12.5 mg and 17.5 mg against placebo. The phase III program is expected to provide important data on the long-term efficacy and safety of VK2735 in different patient populations.
Viking is on track to start late-stage studies of oral VK2735 by the end of this year, following encouraging phase II VENTURE-Oral results.
Competition in Targeted Markets Remains a Concern
Viking is developing the candidate as a potential alternative to established GLP-1 products marketed by pharma giants Eli Lilly (LLY - Free Report) and Novo Nordisk (NVO - Free Report) . Both companies are already marketing oral and injectable obesity treatments. Lilly markets injectable Zepbound and oral Foundayo, while Novo Nordisk markets injectable Wegovy and its oral Wegovy pill.
The competitive landscape is also evolving rapidly. Lilly recently reported results for EloraTZP, an investigational combination of eloralintide, a selective amylin receptor agonist and Zepbound. Data from a phase IIb study showed that all EloraTZP combinations met the primary and secondary endpoints, delivering substantial weight loss and A1C reductions at 48 weeks. LLY plans to advance the candidate into phase III development in the fourth quarter of 2026.
Meanwhile, Novo Nordisk has submitted CagriSema to the FDA for weight management. The once-weekly treatment combines semaglutide with cagrilintide, a long-acting amylin receptor agonist. A final decision is expected before this year’s end.
VKTX's Zacks Rank
Viking currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.